Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy

F. Wei1,2,3,4, J. Yan1,2,3,4 and D. Tang1,2,3,4

1Division of Nephrology, Department of Medicine; 2Division of Urology, Department of Surgery, McMaster University; 3Father Sean O’Sullivan Research Institute; 4the Hamilton Center for Kidney Research, St. Joseph’s Hospital, Hamilton, Ontario, Canada; 5The Genetics Laboratory, Institute of Women and Children’s Health, Longgang District, Shenzhen, Guangdong, P.R. China

Abstract: The Raf-MEK-ERK pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated kinases (ERKs) being a common downstream target of growth factor receptors, Ras, and Raf. Elevation of these up-stream signals occurs frequently in a variety of malignancies and ERK kinases play critical roles in promoting cell proliferation. Therefore, inhibition of MEK-mediated ERK activation is very appealing in cancer therapy. Consequently, numerous MEK inhibitors have been developed over the years. However, clinical trials have yet to produce overwhelming support for using MEK inhibitors in cancer therapy. Although complex reasons may have contributed to this outcome, an alternative possibility is that the MEK-ERK pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy. Recent developments may support this alternative possibility. Accumulating evidence now demonstrated that the MEK-ERK pathway contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression. During DDR, the MEK-ERK pathway is commonly activated, which facilitates the proper activation of DDR checkpoints to prevent cell division. Inhibition of MEK-mediated ERK activation, therefore, compromises checkpoint activation. As a result, cells may continue to proliferate in the presence of DNA lesions, leading to the accumulation of mutations and thereby promoting tumorigenesis. Alternatively, reduction in checkpoint activation may prevent efficient repair of DNA damages, which may cause apoptosis or cell catastrophe, thereby enhancing chemotherapy’s efficacy. This review summarizes our current understanding of the participation of the ERK kinases in DDR.

Keywords: ERK1/2 kinases, DNA damage response (DDR), checkpoint activation, ATM, ATR.

1. INTRODUCTION

DDR guards genome integrity via sensing DNA lesions, activating checkpoints to halt cell cycle progression, and repairing DNA damage [1]. This process is initiated and coordinated by two apical kinases, ataxia-telangiectasia mutated (ATM) and ATR (ATM- and Rad3-related). ATM and ATR subsequently upregulate p21CIP1, an inhibitor of cyclin-dependent kinases (Cdks) [2, 3] and activate checkpoint kinases 1/2 (CHK1/2). CHK1/2 then inactivates Cdc25C which is required for the activation of Cdk1 and Cdk2 [4]. Collectively, the activation of ATM and ATR initiates checkpoints to prevent cell cycle progression [1].

Consistent with ERK kinases being a major player in promoting cell cycle progression [5], ERK1 and ERK2 also contribute to DDR [6]. A variety of genotoxic agents have been shown to activate the ERK kinases and ERK activity modulates DDR [7]. Consistent with the apical roles of ATM and ATR in DDR, DNA damage-induced ERK activation has been reported to be a downstream event of ATM and ATR [8, 9]. On the other hand, ERK activation also facilitates the activation of ATM and ATR [10, 11]. The impact of the MEK-ERK pathway on checkpoint activation in DDR is cell type dependent [6]. While ERK activity facilitates DNA damage-induced cell cycle arrest and apoptosis in a several mammalian cell lines and Drosophila [12, 7, 13, 9, 14, 15], ERK activation also prevents DNA damage-induced apoptosis in myeloma and leukemia [16, 17]. In this review, we will briefly discuss the ERK system, ATM/ATR-initiated DDR, and experimental evidence showing the interplay between ERK and DDR. Finally, we will briefly discuss strategies of using MEK inhibitors in cancer therapy.

2. THE CORE FEATURES OF ATM AND ATR ACTIVATION DURING DDR

DNA damage response is the critical surveillance mechanism that maintains genome integrity and ensures the accurate transmission of genetic information between generations in eukaryotic cells. DDR is mediated by three apical PI3 kinase related kinases (PIKKs), ATM, ATR, and DNA-PKcs (CS: catalytic subunit) [1]. PIKKs possess typical structural features, including the FRAP-ATM-TRRAP (FAT), kinase, and C-terminal FAT (FATC) domain [18, 19]. In line with these structural features, activation of PIKKs share common features, including the interactions with specific proteins and the association with unique DNA lesions [20].

ATM activation is induced by double stranded DNA breaks (DSBs). In human cells, ATM exists as an inactive dimer, which is converted into active monomers in response to DSBs via autophosphorylation at serine 1981 (S1981) [21]. This autophosphorylation stabilizes the association of ATM with DSBs [22]. Accumulating evidence demonstrates that the MRE11-RAD50-NBS1 (MRN) complex plays a pivotal role in ATM signalling. Patients with Nijmegen Breakage Syndrome (NBS) or Ataxia-Telangiectasia-like Disorder (ATLK) display similar clinical and cellular phenotypes with AT patients, including microcephaly, immunodeficiency, being prone to the development of malignancy, sensitization to ionizing radiation (IR), genomic instability and checkpoint defects following DNA damage. These three diseases are caused by mutations in NBS1, MRE11, and ATM, respectively [23]. These observations, therefore, provide strong genetic and cellular evidence showing that the MRN complex and ATM are involved in the same DDR pathway. Biochemically, the MRN complex directly interacts with ATM, resulting in ATM being recruited to DSBs [24, 25, 26], and converting ATM from inactive dimers to active monomers [24, 27]. This association of ATM and the MRN complex is mediated by a direct interaction between ATM and NBS1 [28]. The association with the MRN complex at DSBs activates ATM [27] and ATM subsequently phosphorylates numerous targets to coordinate checkpoint activation and DNA damage repair [1].

While ATR is activated by multiple types of DNA lesions, including DSBs, base adducts, crosslinks, and replication stress [18]; its activation is primarily mediated by the structure containing single-stranded DNA (ssDNA) [29, 30]. Association of ATR with replication protein A (RPA)-coated ssDNA is required for ATR activation. ATR binds directly to the ATR interacting protein (ATRIP). This association does not depend on DNA damage but is
required for the stabilization of both ATR and ATRIP, as function depends on ATRIP in human cells and its homologues in yeast, Rad26 in Schizosaccharomyces pombe and DDC2/LCD1/PIE1 in Saccharomyces cerevisiae. Loss of ATRIP in yeast and human cells recapitulate the same phenotypes as loss of ATR [31, 32, 33, 34, 35, 36]. ATRIP binds to RPA-coated ssDNA and thereby results in the recruitment of ATR to the DNA lesion [30, 37, 38]. Although the association of the ATR-ATRIP complex with RPA-coated ssDNA is required, it is insufficient to increase ATR-derived kinase activity. Biochemical analysis revealed that TOPBP1 (topoisomerase-binding protein 1), the mammalian homologue of yeast Cut5/Dbp11, significantly enhanced the kinase activity of the ATR-ATRIP complex in vitro [39]. In line with the RPA-coated ssDNA being the primary structural link to ATR activation; TOPBP1 is recruited to RPA-coated ssDNA independent of the ATR-ATRIP complex, and requires the Rad17/RFC (replication factor C) and the Rad9-Rad1-Hus1 (9-1-1) complex. Rad17/RFC binds to RPA-ssDNA (Fig. 1) [40, 20], which loads the 9-1-1 complex [41, 42] and subsequently recruits TOPBP1 [43, 44]. This recruitment allows TOPBP1 to activate ATR via binding to both ATR and ATRIP subunits (Fig. 1) [39, 45]. ATR activation coordinates a global cellular response to prevent cell cycle progression into mitotic phase (S phase arrest or induction of apoptosis) and to initiate DNA damage repair [18]. ATR accomplishes these multiple functions by phosphorylation of a variety of down-stream targets, including the serine 139 (S139) in the SQE motif located on the tail of histone H2AX (H2AX), the S15 of p53, and the S345 of CHK1 [1, 46, 47].

Fig. (1). An illustration of ATR activation. 1) The ATR-ATRIP complex binds to RPA-ssDNA; 2) Rad17/RFC, 9-1-1, and TOPBP1 are sequentially loaded onto RPA-ssDNA; 3) TOPBP1 interacts with the ATR-ATRIP complex, resulting in ATR activation.

3. ERK KINASES PLAY A ROLE IN DDR

It is well recognized that DDR is intimately linked to cell division. One of the major tasks of ATM and ATR activation is to initiate checkpoint controls to halt cell cycle progression in order to coordinate the repair of DNA lesions [1]. Activation of checkpoints leads to the up-regulation of p21Cip1 and the inactivation of CDC25C via activation of CHK1 and CHK2 [48, 1]. These events collectively inhibit the kinase activity of Cdk1 and Cdk2, leading to cell cycle arrest. Therefore, inhibition of Cdk activity or arrest of cell division is a downstream event of ATM and ATR. Recent developments, however, demonstrated that cell division contributes more to DDR than only being a downstream event. Cdk activity promotes the proper activation of ATM and ATR in response to DNA damage [49, 50]. This may explain, at least in part, a long-term observation that malignant cells are more sensitive to genotoxic agents than cells in normal tissues [51]. Direct evidence supporting this concept was the recent demonstration that directly blocking cell division via loss of CDC25 protected intestinal mucosa from damage induced by irinotecan, a commonly used chemotherapeutic/genotoxic agent in treating patients with colon cancer [52]. Consistent with the theme that the mechanism regulating cell proliferation actively engages DDR, ERK1 and ERK2 kinases, also contributes to DDR via mechanisms that are dependent or independent on p53 as well as being downstream of ATM and ATR or facilitates the activation of ATM and ATR.

3.1. ERK MAP Kinases

ERK1 and ERK2 (ERK1/2) kinases belong to the mitogen-activated protein kinase (MAPK) family and are activated by two highly conserved upstream kinases, MEK1/2 (MAPK kinase). In addition, MEK1/2 kinases are activated by Raf (MAPK kinase kinase) [53, 54]. MEK1/2 activates ERK1/2 kinases through phosphorylation of threonine 183 (Thr183) and tyrosine 185 (Tyr185) at the Thr-Glu-Tyr site [54]. In addition to the Raf and MEK upstream kinases, ERK activation is facilitated by scaffolding proteins. One such protein is the kinase suppressor of Ras 1 (KSR1) which binds to MEK and thereby facilitates ERK activation [53, 55, 56]. ERK functions in multiple signalling pathways via the phosphorylation of numerous target proteins involved in cell proliferation, differentiation, and apoptosis [53, 57, 58]. In addition, ERK1 and ERK2 achieve substrate specificity using two mechanisms. ERK1 and ERK2 phosphorylates serine/threonine (S/T) residues that are immediately followed by a proline (P) (S/T-P motif) [59, 60]. Many ERK substrates contain one or two docking sites to facilitate their association with ERK, thereby enhancing their phosphorylation [53, 61]. The consensus docking sites for MEK (docking site for ERK and JNK, LX), and DEF (docking site for ERK, FXFP) are (R/K)_{2}X_{2}-LXL (X: any residue) [61] and FXFP [62, 53], respectively.

3.2. ERK Modulates DDR in a Cell-Dependent Manner

Activation of ERK1/2 is commonly observed in multiple cell lines by a variety of genotoxic agents. Etoposide (ETOP), adriamycin, UV, ionizing radiation (IR), hydroxyurea (HU), and mitomycin C (MMC) were shown to activate ERK1/2 in mouse embryonic fibroblast (MEFs), NIH3T3, MCF7, H9c2, U87, keratinocytes, and normal human diploid fibroblasts (IMR90 and 501T) [7, 13, 63, 64, 9, 8, 65, 66]. Both ETOP and IR induced ERK activation reaching a plateau at one hour in MEFs [7, 63]. However, cisplatin activated ERK in HeLa, A2780, and HEI-OC1 auditory cells [12, 67, 68], which was observed at 15 minutes and reached a peak at 30 minutes [68]. Activation of ERK was also observed in T98G cells in response to cisplatin and UV [69]. In addition, BRCA1, which induces the activation of CHK1 and WEE1, also activated ERK [70]. Collectively, the kinetics of ERK activation induced by a variety of DNA damage reagents are regulated by cellular contents during DDR.

ERK activity also modulates checkpoint activation in a cellular context-dependent manner. Inhibition of ERK activation with the commonly used MEK inhibitors (PD98059 and U0126) and a dominant negative MEK1K97M attenuates ETOP and HU-induced G2/M and S phase arrest in several cell lines, including NIH3T3, MCF7, MEF, and HCT116 [7, 13, 9]. Consistent with these observations, knockdown of either ERK1 or ERK2 compromises ETOP and HU-induced G2/M and S phase arrest in MCF7 cells [10, 11]. Conversely, enforced activation of ERK1/2 using a
TopBP1 for ATR [76, 45, 20]. However, the detailed mechanism responsible for ATM and ATR activation in DDR remains largely elusive. It is thus intriguing that DNA damage-induced ERK activation contributes to the activation of ATM and ATR.

Cisplatin was reported to robustly activate ERK in human ovarian carcinoma A2780 cells. Inhibition of ERK activation using PD98059 reduced the phosphorylation of p53 at S15 in response to cisplatin [67]. In addition, inhibition of ERK activation with U0126 decreases doxorubicin-induced p53 S15 phosphorylation in H9c2 cells [64]. As S15 is not followed by a proline (P), it is thus very unlikely that ERK1/2 can directly phosphorylate p53 S15. The S15 is followed by QE (15-SQE-17) (http://www.uniprot.org/uniprot/P04637). Consistent with the S/T-QE sequence is the well demonstrated phosphorylation site for ATM and ATR [1], p53 S15 is phosphorylated by ATM/ATR in DDR [1]. It is thus, likely that ERK enhances p53 S15 phosphorylation, as reported by Persons et al. [67] and Liu et al. [64], via facilitation of the activation of ATM and or ATR. This possibility is supported by the observation that IR-induced nuclear foci of S1981 phosphorylated ATM was significantly reduced in U87 cells when ERK activation was inhibited by PD184352, a MEK inhibitor [8]. A similar observation was also reported in MCF7 cells. U0126 (one of most commonly used MEK inhibitors) compromises IR-induced ATR activation as well as the downstream events of ATR, including CHK1 activation, CDC25 inactivation, and CDC2 inactivation [9]. Consistent with ERK1/2 being the major, if not the sole targets of MEK [53], it was recently demonstrated that knockdown of either ERK1 or ERK2 significantly reduced ATM activation (ATM S1981 phosphorylation and the nuclear foci of S1981 phosphorylated ATM) in response to ETOP, and thereby attenuated phosphorylation of the ATM substrates, including the S139 of H2AX (γH2AX), S15 of p53, and T68 of CHK2. As CHK2 inactivates CDC25C via phosphorylation of CDC25C S216, resulting in G2/M arrest [46, 3, 4], knockdown of either ERK1 or ERK2 reduced ETOP-induced CDC25C S216 phosphorylation and significantly compromised ETOP-induced G2/M arrest in MCF7 cells [10].

Hydroxyurea (HU) induces stalled replication forks, which primarily activates ATR to initiate the S-phase checkpoints [77]. HU activated ERK kinase in MCF7 cells, which facilitated ATR activation [77]. Additionally, inhibition of ERK activation by using MEK inhibitors (PD98059 and U0126) and a dominant negative MEK1K97M reduced ATR nuclear foci, phosphorylation of ATR targets [p53 S15 and H2AX S139 (γH2AX)], S phase arrest in response to HU in NIH3T3, MCF7, MEF, and HCT116 cells [13]. The inhibition of ERK activation also attenuated CDC2 tyrosine (Y) 15 phosphorylation induced by HU [13, 11]. Phosphorylation of Y15 inactivates CDC2, whose activity is required for mitotic entry [78]. Therefore, inhibition of ERK activation may reduce HU-induced S phase arrest by improperly facilitating CDC2 activation. Conversely, ectopic expression of a constitutively active MEK1Q56S sensitized HU-induced formation of the nuclear foci of ATR and γH2AX [13]. Furthermore, knockdown of either ERK1 or ERK2 reduced HU-induced ATR activation, CHK1 S345 phosphorylation, p53 S15 phosphorylation, and γH2AX [11]. This was associated with compromising HU-induced S phase arrest and CDC2 Y15 phosphorylation [11]. Intriguingly, it was observed that knockdown of either ERK1 or ERK2 resulted in a significant accumulation of ATR in the nucleolus when cells were treated with HU. DNA damage was reported to induce protein trafficking in to and out of the nucleolus, thereby regulating DDR [79]. In general, proteins with functions in promoting DDR, including p14ARF [80], WRN ( Werner Syndrome Protein) [81, 82], PARP-1 (Poly(ADP-ribose) polymerase-1) [83], and BRCA1 [84], translocate from the nucleoli to nucleoplasm upon DNA damage. However, proteins that inhibit DDR, like MDM2, relocate from the nucleoplasm into the nucleolus [85].
Therefore, the net result of these protein traffics is to promote DDR. It is thus plausible that the observed relocation of ATR to the nucleolus in HU-treated ERK1 or ERK2 knockdown cells may sequester ATR in the nucleoli. This would be consistent with the observation that the reduction of either ERK1 or ERK2 has no effect on HU-induced recruitment of RPA60 to ssDNA, indicating that ERK kinases may not play a major role in the formation of RPA-coated ssDNA [11]. Taken together, accumulating evidence demonstrates that ERK1/2 facilitates DNA damage-induced ATR activation.

4. FUTURE PERSPECTIVES IN ERK-FACILITATED DDR

Research carried out in the last decade gradually consolidated the contributions of the MEK-ERK kinases to DDR. While being heavily investigated for a long period of time, the underlying mechanisms whereby DNA damage activates ATM and ATR, two apical kinases in DDR, remain unclear. The ERK kinases may add to the missing pieces regarding how DNA lesions activate ATM and ATR. ERK kinases facilitate the activation of apical ATM or ATR kinases in response to a variety of DNA damages (Fig. 2). In the case of ATR, ERK kinases facilitate ATR activation at least in part by preventing the accumulation of ATR in the nucleolus (Fig. 2). While the observations that MEK-ERK kinases facilitate the proper activation of ATM and ATR do add to the importance of ERK in DDR regulation, the underlying mechanisms remain to be determined. Will ERK directly phosphorylate ATM/ATR or indirectly phosphorylate other components that are involved in ATM/ATR activation? Will these phosphorylations play major roles in ATM/ATR activation? The ATM protein contains several potential ERK phosphorylation sites (S/T-P) and 2 potential ERK docking sites, DEJL domains ([150-1RSVLTL-1157 and 2302-KKEQLAL-2309]). These sites map to the consensus sequence for the DEJL domain (R/K)2X2-LXL [61]. The phosphorylation of ATR at S428 was reported in DDR [86]. We have shown that HU robustly induces ATR S428 phosphorylation and that knockdown of ERK1 or ERK2 dramatically reduces this event (Fig. 3). The kinases that phosphorylate S428 and the impact of this event on ATR function remain unknown. However, S428 is followed by a proline (P) (DGISPKRRR), a site that matches the substrate specificity of ERK kinases [59]. Additionally, human ATR contains a candidate DEF motif, 983-FDFP-985. This site matches the consensus of the DEF ERK docking site FXXF [62, 53]. It is thus a possibility that ERK may phosphorylate ATR at S428.

Fig. (2). A model illustrating ERK-facilitated activation of ATM and ATR during DDR. 1) DNA lesions lead to activation of ATM, ATR, and ERK; 2) ERK facilitates ATM activation; 3) ERK executes the proper ATR activation at least in part by ensuring ATR stay in the nucleoplasm.

5. OPTIMIZATION OF MEK INHIBITORS INVOLVED IN CANCER THERAPY

Ras and Raf [54], ERK kinases are commonly activated abnormally in most human cancers due to the converging site in transmitting signals derived from growth factors. The amplification of upstream growth factor receptors takes place frequently in cancer, including the epidermal growth factor receptor (EGFR) in solid tumors [87] and BCR-ABL [fusión of the Ab1 oncogene on chromosome 9 to the BCR (breakpoint cluster region) gene on chromosome 22] in chronic myeloid leukemia (CML) [88]. Additionally, the amplification of the ras oncogene is detected in approximately 30% of human cancers [89]. Mutations leading to the activation of BRAF (the B isoform of RAF) were detected in 27-70% of melanoma, 36-53% of papillary thyroid cancer, 5-22% of colorectal cancer, and 30% of ovarian cancer [90]. In line with abnormal activation of the ERK kinases being one of the common events in human cancers, ERK kinases are well regarded to drive cancerous cell proliferation and promote other oncogenic events, including survival and angiogenesis [91, 92]. Therefore, inhibition of MEK-mediated ERK activation may be an effective option in cancer therapy. Indeed, several highly specific MEK inhibitors have been developed, including PD184352/CI-1040 (Pfizer), PD0325901 (Pfizer), AZD6244 (ARRY-142886 or Selumetinib) (Astra Zeneca) and RDEA119 (Ardea Biosciences) [93]. While these small molecule MEK inhibitors are highly specific and effective in preclinical settings, they are, however, not effective in clinical trials on a variety of tumors. PD184352, the first MEK inhibitor entering clinical trials, failed to show encouraging results when treating patients with advanced non-small cell lung, breast, colon, and pancreatic cancer [94]. PD0325901 also did not produce overwhelming positive outcomes in clinical trials on patients with breast, colon, melanoma, and non-small cell lung cancer (NSCLC) [95, 96]. This was also the situation for a newly developed MEK inhibitor AZD6244 when examined in clinical trials on melanoma and NSCLC [97, 98]. While better designed clinical trials on selected patients with tumors that are dictated to ERK activation caused by BRAF or KRAS activation [99, 100], might have yielded more positive outcomes, it is uncertain how the potential positive results might be. This is because 1) in clinical trials on melanoma, only 12% of tumors with BRAF mutations were partially responsive to AZD6244 [97], 2) NSCLCs with KRAS mutations display heterozygous responses to MEK inhibitors, and 3) a minor proportion (21%) of patients having BRAF V600 mutation showed responses to the MEK inhibitor GSK1120212 [101, 102]. Taken together, clinical trials using a variety of MEK inhibitors were unable to produce outcomes that are proportional to the prevalence of ERK activation in human cancers.

Although there are complex factors that are certainly contributing to the lack of success for MEK inhibitors, such as the design of clinical trials, limitation of tolerable doses being used, and the development of resistance. The role of ERK in tumorigenesis may also be a contributing factor. ERK activity is widely regarded to provide proliferation signals to cancerous cells, the main underlying reason to target ERK activation by using MEK inhibitors. However, recent developments have clearly demonstrated that ERK kinases play an important role in DNA damage response (DDR). This is consistent with the observation that activation of the RAP-MEK-ERK pathway is commonly associated with chemotherapy and radiotherapy [103] as chemotherapeutic drugs commonly induce DNA damage [104]. Therefore, applications involving MEK inhibitors in cancer therapy should be considered very carefully as maintaining genome integrity is a driving force of tumor suppression.

The contribution of ERK to DDR outlines a scientific background for a combinational therapy involving genotoxic drugs and MEK inhibitors. As DNA damage-induced ERK activation
inhibited DDR-associated apoptosis in myeloma and leukemia [16, 17], inhibition of ERK activation will be expected to enhance the efficacy of genotoxic drugs on these cancers. However, for tumors not associated with the hematopoietic system, ERK activation sensitizes DNA damage-induced checkpoint activation [7, 9-15, 69, 71, 72]. Therefore, inhibition of ERK activation in these cancers may also enhance the genotoxic effect of chemotherapeutic drugs. This may be caused by the accumulation of DNA lesions due to impaired checkpoint activation when ERK activation is inhibited. This concept is supported by a recent report showing that the MEK inhibitor AZD6244 enhanced radiation-induced reduction of A549-derived xenograft tumors [105]. However, inhibition of ERK may compromise checkpoint activation and thereby allowing cells to proliferate in the presence of DNA lesions. This may lead to accumulation of mutations and thus contribute to cancer progression, which might be attributable to the resistance or the inefficiency of MEK inhibitors in cancer therapy. Therefore, a key factor in determining a regime of MEK inhibitors and genotoxic drugs in treating solid cancers is whether this combinational therapy will lead to a catastrophic result due to inefficient repair of DNA lesions or continuous cell proliferation in the presence of DNA lesions.

ACKNOWLEDGEMENTS
This work was supported by a CIHR grant (MOP – 84381) to D. Tang. We also like to acknowledge the financial support from St. Joseph’s HealthCare at Hamilton, Ontario, Canada to the Hamilton Centre for Kidney Research (HCKR).

REFERENCES
[1] Zhou, B.B.; Elledge, S.J. The DNA damage response: putting checkpoints in perspective Nature 2000, 408, 433-439.
[2] Sherr, C.J.; Roberts, J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13, 1501-1512.
[3] Bhattacharya, S.; Ray, R.M.; Johnson L,R. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal. 2009, 21(4), 509-522.
[4] Peng, C.Y.; Graves, P.R.; Thoma, R.S.; Wu, Z.; Shaw, A.S.; Pwnica-Worms, H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277, 1501-1505.
[5] Meloche, S.; Pouyssegur, J. The ERK1/2 mitogen-activated protein pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26, 3227-3239.
[6] Dent, P.; Yacoub, A.; Fisher, P.B.; Hagan, M.P.; Grant, S. MAPK pathways in radiation responses. Oncogene 2003, 22, 5885-5896.
[7] Tang, D.; Wu, D.; Hirao, A.; Lahti, J.M.; Liu, L.; Mazzu, B.; Kidd, V.J.; Mak, T.W.; Ingram, A.J. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 2002, 277, 12710-12717.
[8] Golding, S.E.; Rosenberg, E.; Neill, S.; Dent, P.; Povirk, L.F.; Valeri, K. Extracellular signal- related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 2007, 67, 1046-53.
[9] Yan, Y.; Black, C.P.; Cowan, K.H. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 2007, 26, 4698-4698.
[10] Wei, F.; Xie, Y.; Tao, L.; Tang, D. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal. 2010, 22, 1783-1789.
[11] Wei, F.; Xie, Y.; Lihz, H.; Tao, L.; Tang, D. ERK1 and ERK2 kinases activate hydroxyurea-induced S-phase checkpoint in MCF7 cells by mediating ATR activation. Cell Signal. 2011, 23, 259-268.
[12] Wang, X.; Martindale, J.L.; Holtbrook, N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000, 275, 39435-39443.
[13] Wu, D.; Chen, B.; Parihar, K.; He, L.; Fan, C.; Zhang, J.; Liu, L.; Gillis, A.; Bruce, A.; Kapoor, A.; Tang, D. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. Oncogene 2006, 25, 1153-1164.
[14] Lee, J.H.; Kim, K.T. Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death. J Cell Physiol. 2007, 210, 784-797.
[15] Mogila, V.; Xia, F.; Li, W.X. Regulation of cyclin-dependent kinase 5 and p53 by MEK and ERK in Drosophila. Dev Cell 2006, 11, 575-582.
[16] Dai, Y.; Chen, S.; Pei, X.Y.; Almenara, J.A.; Kramer, L.B.; Venditti, C.A.; Dent, P.; Grant, S. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor- induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008, 112, 2439-2449.
[17] Nishioka, C.; Ikese, T.; Yang, J.; Yokoyama, A. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis 2009, 14, 1108-1120.
[18] Cimprich, K.A.; Cortez, D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008, 9, 616-27.
[19] Lempiäinen, H.; Halazonetis, T.D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28, 3067-3073.
[20] Burrows, A.E.; Elledge, S.J. How ATR turns on: TopBP1 goes on ATRIP with ATR. Genes Dev. 2008, 22, 1416-1421.
[21] Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421, 499-506.

Fig. (3), ERK facilitates ATR S428 phosphorylation in response to HU. A) MCF7 cells were stably infected with empty vector (Ctrl), ERK1 shRNA, and ERK2 shRNA. The expression of ERK1, ERK2, and actin was examined by western blot using the specific antibodies. B) MCF7 Ctrl (control), ERK1 shRNA and ERK2 shRNA cells were treated with HU at the indicated doses for 24 hours, followed by analysis of ATR S428 phosphorylation (Phos-S428 ATR) (Cell Signaling, 1:1000) and total ATR (Calbiochem, 1:1000).
Johnson, N.; Shapiro, G.I. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets. 2010, 14, 327-346.

Bolderson, E.; Richard, D.J.; Zhou, B.B.; Khanna, K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009, 15, 6314-6320.

Lee, J.H.; Paull, T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 2005, 308, 551-554.

Johnson, N.; Shapiro, G.I. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets. 2010, 14, 327-346.

Bolderson, E.; Richard, D.J.; Zhou, B.B.; Khanna, K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009, 15, 6314-6320.

Lee, J.H.; Paull, T.T. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 2005, 308, 551-554.
Akt in response to DNA double-strand breaks. *Cell Cycle* 2011, 10, 481-491.

Cortez, D. Unwind and slow down: checkpoint activation by helicase and polymerase uncoupling. *Genes & Dev* 2005, 19, 1007-1012.

Segurado M, Tercero JA. The S-phase checkpoint: targeting the replication fork. *Biol Cell* 101, 617-27, 2009.

Chen, Y.; Sanchez, Y. Chk1 in the DNA damage response: conserved roles from yeasts to mammals. *DNA Repair* 2004, 3, 1025-1032.

Tembe, V.; Henderson, B.R. Protein trafficking in response to DNA damage. *Cell Signal* 2007, 19, 1113-1120.

Lee, C.; Smith, B.A.; Bandyopadhyay, K.; Gjerset, R.A. DNA damage disrupts the p14ARF-B23 (nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. *Cancer Res.* 2005, 65, 9834-9842.

Karmakar, P.; Bohr, V.A. Cellular dynamics and modulation of WRN protein is DNA damage specific. *Mech Ageing Dev.* 2005, 126, 1146-1158.

Li, F.J.; Barchowsky, A.; Opresko, P.L. The Werner syndrome protein functions in repair of Cr(VI)-induced replication-associated DNA damage. *Toxicol Sci.* 2009, 110, 307-318.

Rancourt, A.; Satoh, M.S. Delocalization of nucleolar poly(ADP-ribose) polymerase-1 to the nucleoplasm and its novel link to cellular sensitivity to DNA damage. *DNA Repair* 2009, 28, 286-297.

Tulchin, N.; Chambon, M.; Juan, G.; Chambon, M.; Tulchin, N.; Chambon, M.; Juan, G.; Dikman, S.; Strauchen, J.; Ornstein, L.; Rancourt, A.; Satoh, M.S. Delocalization of nucleolar poly(ADP-ribose) polymerase-1 to the nucleoplasm and its novel link to cellular sensitivity to DNA damage. *DNA Repair* 2009, 28, 286-297.

Karmakar, P.; Bohr, V.A. Cellular dynamics and modulation of WRN protein is DNA damage specific. *Mech Ageing Dev.* 2005, 126, 1146-1158.

Pao, W.; Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Clin Cancer Res.* 2010, 16(8), 2450-2457.

Ricart, E.B.; Ricart, J.J.; Nabel, J.M.; Malbarg, L.; Chapman, P.B.; DePrimo, S.E.; Bentivegna, S.; Wilner, K.D.; Tan, W.; Ricart, A.D. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor D-0325901 in patients with advanced cancers. *Clin Cancer Res.* 2010, 16(6), 1924-1937.

Garber, K. Trial offers early test case for personalized medicine. *J Natl Cancer Inst.* 2009, 101(3), 136-138.

Dy, G. MEK/MAPK inhibitors. *J Thorac Oncol.* 2010, 5(12 Suppl 6), S474-475.

Solit, D.B.; Garraway, L.A.; Pratilas, C.A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J.M.; She, Y.; Osman, I.; Golub, T.R.; Sebott-Leopold, J.; Sellers, W.R.; Rosen, N. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 2006, 439, 358-362.

Yoon, Y.K.; Kim, H.P.; Han, S.W.; Oh do, Y.; Im, S.A.; Bang, Y.J.; Kim, T.Y. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. *Mol Carcinog.* 2010, 49(4), 353-362.

Corcoran, R.B.; Settleman, J.; Engelman, J.A. Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. *Oncotarget* 2011, 2(4), 336-346.

Poulakis, P.I.; Rosen, N. Mutant BRAF melanomas--dependence and resistance. *Cancer Cell* 2011, 19(1), 11-15.

Ciccia, A.; Elledge, S.J. The DNA damage response: making it safe to play knives. *Mol Cell* 2010, 40, 179-204.

Chung, E.J.; Brown, A.P.; Asano, H.; Mandler, M.; Burgan, W.E.; Carter, D.; Campaussen, K.; Citron, D. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. *Clin Cancer Res.* 2009, 15(9), 3050-3057.